Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat.
Seventeen adult cats were chronically implanted with electrodes for polygraphic recordings in order to assess the role of catecholamines in the arousal effects of oral administrations of modafinil, a presumed noradrenergic agonist, and amphetamine, a well-known catecholamine-releasing agent. Whereas both modafinil (1, 2.5 and 5 mg/kg) and amphetamine (0.25, 0.5 and 1 mg/kg) caused a significant and dose-dependent increase in wakefulness and brain temperature, amphetamine, but not modafinil, elicited marked signs of behavioral excitation. Pretreatments with alpha-methyl-DL-p-tyrosine methyl ester (50 mg/kg, i.p.), an inhibitor of catecholamine synthesis, almost completely prevented the effects of amphetamine (0.25 and 1 mg/kg), but only slightly reduced the duration of the waking effect of modafinil (2.5 and 5 mg/kg). Pretreatments with phentolamine (10 mg/kg, i.p.), prazosin (1.5 mg/kg, per os) and propranolol (5 mg/kg, i.p.), an alpha-, alpha 1- and beta-receptor antagonist, respectively, attenuated significantly the arousal effect of modafinil (1 mg/kg, the same as below) but not of amphetamine (0.25 mg/kg, the same as below). Intraperitoneal injections of haloperidol (0.5 mg/kg), a dopamine-receptor antagonist, blocked significantly the arousal of amphetamine but not of modafinil. The effects of both modafinil and amphetamine were enhanced by a pretreatment with yohimbine (1 mg/kg, i.p.), an alpha 2-receptor antagonist. These results suggest that the arousal effect of modafinil does not depend on the availability of the endogenous catecholamines but results from an enhancement of alpha 1- and beta-receptor activity and that the waking and behavioral effects of amphetamine may be mainly due to an increase in dopamine release.
Département de Médecine Expérimentale, INSERM U52, CNRS URA 1195, Faculté de Médecine, Université Claude Bernard, Lyon, France.
J S
JS
Lin
B
B
Roussel
H
H
Akaoka
P
P
Fort
G
G
Debilly
M
M
Jouvet
D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001143:Arousal / Q000187:drug effects; D001559:Benzhydryl Compounds / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects*; D001921:Brain / Q000187:drug effects; D002395:Catecholamines / Q000502:physiology*; D002415:Cats; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D005260:Female; D008297:Male; D000077408:Modafinil; D014851:Wakefulness / Q000187:drug effects*
D001559:Benzhydryl Compounds; D002395:Catecholamines; D000697:Central Nervous System Stimulants; D000661:Amphetamine; D000077408:Modafinil